Antithrombin-heparin conjugate
Alternative Names: ATH; Covalent antithrombin-heparin complex; Heparin-antithrombin conjugateLatest Information Update: 24 Sep 2021
At a glance
- Originator Nonindustrial source
- Developer Inflazyme Pharmaceuticals; Nonindustrial source
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors; Thrombin inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Catheter thrombosis; Respiratory distress syndrome; Thrombosis
Most Recent Events
- 27 Jul 2004 Discontinued - Preclinical for Thrombosis in Canada (unspecified route)
- 15 Mar 2004 This compound is still in active development - (BPN-2004)
- 15 Mar 2004 ATHt is available for licensing worldwide (www.inflazyme.com)